U.S., Eli Lilly Forge Deal for COVID-19 Antibody Drug
Eli Lilly has landed a $375 million contract from the U.S. government to supply 300,000 vials of its investigational COVID-19 treatment, LY-CoV555 (bamlanivimab).
The FDA is currently reviewing Lilly’s application for Emergency Use Authorization of the neutralizing antibody as an early-stage treatment for high-risk patients.
Delivery will occur over two months, if approved, with an option for an additional 650,000 vials through the end of June 2021.
LY-CoV555 has shown mixed results so far in clinical trials. The National Institute of Allergy and Infectious Diseases has halted a trial of the antibody in combination with remdesivir after the trial’s independent data and safety monitoring board found no clinical benefit.